Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ezogabine (retigabine)


Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Structure of ezogabine.


  1. 1

    Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nature Rev. Drug Discov. 9, 68–82 (2010).

    CAS  Article  Google Scholar 

  2. 2

    Rostock A. et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23, 211–223 (1996).

    CAS  Article  Google Scholar 

  3. 3

    Rundfeldt, C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. 336, 243–249 (1997).

    CAS  Article  Google Scholar 

  4. 4

    US Food and Drug Administration. FDA labeling information — Potiga. FDA website [online], (2011).

  5. 5

    European Medicines Agency (EMA). European Public Assessment Report — Trobalt. EMA website [online], (2011).

  6. 6

    Porter, R. J. et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68, 1197–2004 (2007).

    CAS  Article  Google Scholar 

  7. 7

    French, J. A. et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76, 1555–1563 (2011).

    CAS  Article  Google Scholar 

  8. 8

    Brodie, M. J. et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75, 1817–1824 (2010).

    CAS  Article  Google Scholar 

  9. 9

    Schmidt, D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 11, 9–11 (2011).

    Article  Google Scholar 

  10. 10

    Faught, E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 11, 75–78 (2011).

    Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Carl E. Stafstrom, Seden Grippon or Peter Kirkpatrick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stafstrom, C., Grippon, S. & Kirkpatrick, P. Ezogabine (retigabine). Nat Rev Drug Discov 10, 729–730 (2011).

Download citation

Further reading


Quick links